The Mechanism of TCF7L2 and SLC30A8 on Antipsychotic-induced Metabolic Syndrome

• Conditions: Schizophrenia; Metabolic Syndrome

• Registration Number: NCT02093858
• Lead Sponsor: Central South University

Brief Summary

Almost all of antipsychotics can induce metabolic syndrome,Genetic factors play a key role in the development of metabolic syndrome,TCF7L2 and SLC30A8 are strongestly correlated with metabolic syndrome.Moreover,Antipsychotics have an effect on the expression of TCF7L2 and SLC30A8 genes.It indicates the variations of TCF7L2 and SLC30A8 play an important part in the development of antipsychotics-induced metabolic syndrome.

Detailed Description

* In this study, we will determine the effect of olanzapine on the expression of TCF7L2 and SLC30A8.

* The relationship of the polymorphism of TCF7L2 and SLC30A8 with antipsychotic-induced metabolic syndrome in schizophrenia patients.

Study Timeline

• Status Verified: 2014-03
• Study First Submitted: 2014-03-20
• Study First Submitted QC: 2014-03-20
• Last Update Submitted: 2014-03-20
• Study First Posted: 2014-03-21
• Last Update Posted: 2014-03-21
• Study Start: 2014-04
• Primary Completion: 2017-12
• Study Completion: 2017-12

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 212

Inclusion Criteria

• Clinical diagnosis of first episode schizophrenia
• Must be able to swallow tablets
• Take only one antipsychotics

Exclusion Criteria

• liver or renal or cardiovascular diseases
• pregnant or lactating women
• drug and alcohol dependence

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Change in weight and blood glucose	24 weeks

Secondary Outcome Measures

Name	Time	Method
Change of the blood pressure and blood lipid	24 weeks

Trial Locations

Locations (1)

Mental Health Institute; 🇨🇳 Changsha, Hunan, China